Epigenetic Perspective of Immunotherapy for Cancers
Immunotherapy has brought new hope for cancer patients in recent times. However, despite the promising success of immunotherapy, there is still a need to address major challenges including heterogeneity in response among patients, the reoccurrence of the disease, and iRAEs (immune-related adverse ef...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/12/3/365 |
| _version_ | 1797624980669726720 |
|---|---|
| author | Sunita Keshari Praveen Barrodia Anand Kamal Singh |
| author_facet | Sunita Keshari Praveen Barrodia Anand Kamal Singh |
| author_sort | Sunita Keshari |
| collection | DOAJ |
| description | Immunotherapy has brought new hope for cancer patients in recent times. However, despite the promising success of immunotherapy, there is still a need to address major challenges including heterogeneity in response among patients, the reoccurrence of the disease, and iRAEs (immune-related adverse effects). The first critical step towards solving these issues is understanding the epigenomic events that play a significant role in the regulation of specific biomolecules in the context of the immune population present in the tumor immune microenvironment (TIME) during various treatments and responses. A prominent advantage of this step is that it would enable researchers to harness the reversibility of epigenetic modifications for their druggability. Therefore, we reviewed the crucial studies in which varying epigenomic events were captured with immuno-oncology set-ups. Finally, we discuss the therapeutic possibilities of their utilization for the betterment of immunotherapy in terms of diagnosis, progression, and cure for cancer patients. |
| first_indexed | 2024-03-11T09:50:21Z |
| format | Article |
| id | doaj.art-b07324bb4ffb40eab0421b8c0537f1a7 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-11T09:50:21Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-b07324bb4ffb40eab0421b8c0537f1a72023-11-16T16:20:34ZengMDPI AGCells2073-44092023-01-0112336510.3390/cells12030365Epigenetic Perspective of Immunotherapy for CancersSunita Keshari0Praveen Barrodia1Anand Kamal Singh2Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USADepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USADepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USAImmunotherapy has brought new hope for cancer patients in recent times. However, despite the promising success of immunotherapy, there is still a need to address major challenges including heterogeneity in response among patients, the reoccurrence of the disease, and iRAEs (immune-related adverse effects). The first critical step towards solving these issues is understanding the epigenomic events that play a significant role in the regulation of specific biomolecules in the context of the immune population present in the tumor immune microenvironment (TIME) during various treatments and responses. A prominent advantage of this step is that it would enable researchers to harness the reversibility of epigenetic modifications for their druggability. Therefore, we reviewed the crucial studies in which varying epigenomic events were captured with immuno-oncology set-ups. Finally, we discuss the therapeutic possibilities of their utilization for the betterment of immunotherapy in terms of diagnosis, progression, and cure for cancer patients.https://www.mdpi.com/2073-4409/12/3/365cancerimmunotherapyepigeneticsimmune checkpoint drugsepigenetic drugs |
| spellingShingle | Sunita Keshari Praveen Barrodia Anand Kamal Singh Epigenetic Perspective of Immunotherapy for Cancers Cells cancer immunotherapy epigenetics immune checkpoint drugs epigenetic drugs |
| title | Epigenetic Perspective of Immunotherapy for Cancers |
| title_full | Epigenetic Perspective of Immunotherapy for Cancers |
| title_fullStr | Epigenetic Perspective of Immunotherapy for Cancers |
| title_full_unstemmed | Epigenetic Perspective of Immunotherapy for Cancers |
| title_short | Epigenetic Perspective of Immunotherapy for Cancers |
| title_sort | epigenetic perspective of immunotherapy for cancers |
| topic | cancer immunotherapy epigenetics immune checkpoint drugs epigenetic drugs |
| url | https://www.mdpi.com/2073-4409/12/3/365 |
| work_keys_str_mv | AT sunitakeshari epigeneticperspectiveofimmunotherapyforcancers AT praveenbarrodia epigeneticperspectiveofimmunotherapyforcancers AT anandkamalsingh epigeneticperspectiveofimmunotherapyforcancers |